Showing 1061-1070 of 1673 results for "".
- Cutera Launches excel V+ the Next Generation Laser Platformhttps://modernaesthetics.com/news/cutera-launches-excel-v-the-next-generation-laser-platform/2471949/Cutera, Inc. has launched its excel V+ laser platform, which the company describes as a technological advancement that includes 50 percent more power and treatment speed, optimized delivery systems and parameters for treating vascular lesions and pigmentation concerns. The company says th
- Evolus: Jeuveau FDA Cleared for Aesthetic Injectionhttps://modernaesthetics.com/news/evolus-jeuveau-fda-cleared-for-aesthetic-injection/2471954/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Revance Shares Positive Efficacy and Duration Data for RT002https://modernaesthetics.com/news/revance-share-positive-efficacy-and-duration-data-for-rt002/2471986/Revance Therapeutics, Inc.'s long-acting neuromodulator daxibotulinumtoxinA for Injection (RT002) with its proprietary stabilizing excipient peptide technology delivered positive top-line results in alleviating moderate to severe glabellar lines in the SAKURA 3 Phase 3 open-label, long-term s
- Novel 1060 Diode Laser Proves Safe and Effective for Hair Removalhttps://modernaesthetics.com/news/novel-1060-diode-laser-proves-safe-and-effective-for-hair-removal/2471992/A novel 1060 nm diode laser system is safe and effective for hair removal and long-term hair reduction in all skin types including darkly pigmented individuals, according to
- Scott Peterson, PhD is Now Head of Medical Affairs at Evolushttps://modernaesthetics.com/news/scott-peterson-phd/2472004/R. Scott Peterson, PhD is now Head of Medical Affairs at Evolus, supporting the strategic development and execution of medical affairs initiatives. Evolus is a company dedicated to aestheti
- xMedica Launches Aesthetics Conference Focused on Energy Based Treatments for Male and Female Sexual Wellnesshttps://modernaesthetics.com/news/xmedica-launches-aesthetics-conference-focused-on-energy-based-treatments-for-male-and-female-sexual-wellness/2472007/Medical education consortium xMedica LLC of Atlanta has developed a new educational initiative, "The Use of Energy-Based Devices for Improving Sexual Health." The overriding goal of this unique conference is to present factual data in a CME setting to address this new are
- ARTAS iX: Real-World Evaluation Study Shows Benefithttps://modernaesthetics.com/news/artas-ix-real-world-evaluation-study-shows-benefit/2472009/Restoration Robotics, Inc. (NASDAQ: HAIR), the global leader in robotic hair restoration, today announced results from a real-world evaluation study of The new ARTAS iX™ Robotic Hair Restoration System demonstrates clinical efficiency in hair harvesting and implan
- Introducing Juvéderm It, Allergan's Newest Ad Campaignhttps://modernaesthetics.com/news/introducing-juvderm-it-allergans-newest-ad-campaign/2472020/Allergan plc is rolling out a new Juvéderm advertising campaign that aims to make this family of fillers a household name. Comprising a modernized logo, a bright, poppy color scheme, an edgy soundtrack and robust social media component, Juvéderm It is the first new adv
- Nestle to Explore Strategic Options for Skin Health Divisionhttps://modernaesthetics.com/news/nestle-to-explore-strategic-options-for-skin-health-division/2472031/...After further analysis and consideration, the Board has come to the conclusion that the future growth opportunities of Nestlé Skin Health lie increasingly outside the Group’s strategic scope
- New for EBD-Based Acne Care: Sebacia Microparticles Clearedhttps://modernaesthetics.com/news/new-for-ebd-based-acne-care-sebacia-microparticles-cleared/2472033/Sebacia Microparticles are now FDA-cleared for use in the treatment of acne. The clearance comes on the heels of a pivotal study demonstrating the clinical safety and efficacy of the micoparticles. Sebacia, Inc. had submitted its 510(k) submission to the FDA in June 2018. Sebacia Mic